Public-health advocacy · Research access
Don't Emergency-Schedule SR-17018 Before It Can Be Studied
DEA has announced intent to place SR-17018 into Schedule I. Many people report that SR-17018 helped them stop opioids with dramatically reduced withdrawal symptoms. These reports are not a substitute for clinical trials, but they are strong enough to justify urgent research, compound-specific review, and a lawful medical pathway rather than emergency prohibition.
What's happening?
- SR-17018 is also known as 5,6-dichloro desmethylchlorphine — this is the DEA's own terminology in its notice.
- DEA has named it in a temporary (emergency) scheduling notice that would place it into Schedule I.
- This advocacy request is NOT about unregulated sales.
- The request is to delay or narrow scheduling of SR-17018 specifically, separate it from other compounds, publish compound-specific evidence, and preserve lawful research and medical-development access.
The core ask
- Delay or narrow the emergency scheduling of SR-17018 specifically.
- Separate SR-17018 from other listed compounds and review it on its own merits.
- Publish the compound-specific evidence being relied upon.
- Preserve lawful research and medical-development access to SR-17018.
- Involve HHS/FDA scientific and medical review before any placement.
- Avoid blocking potential opioid-withdrawal research before it can be studied.
Three ways to make your voice count
Write a letter or email
Generate a personalized message to your representative, senators, DEA, and FDA/HHS in a couple of minutes.
Open the letter builderCall Congress
A 60-second call is fast, personal, and easy for offices to log. Get a ready-to-read script.
Get a call scriptShare responsibly
Spread the campaign with ready-made, careful messaging for social, email, and text.
Open share toolkitStudy it before you schedule it.
This is not a request for unregulated sales, and it is not medical or legal advice. It is a request to preserve lawful research access and require compound-specific review.